ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Shaw’s Lung Cancer, Bronchoalveolar Carcinoma, Exemplifies Elusiveness of 2015 Goal. Little Known About The Rare Disease.

February 3, 2006

NCI Developing Policy On Relations Between Industry, DCT Clinical Trials

July 29, 1983

Natcher Subcommittee Kills Recision, Save NCI $17 Million

May 2, 1980

AACR honors Five With Awards Next Month

April 2, 1993

In Brief: Charles Heidelberger, Sol Spiegelman Both Die of Cancer; Robert Wittes New CTEP Director

January 28, 1983

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

November 26, 2010